SCHEMBL12372537

SCHEMBL12372537

O=C1[C@H]2C[C@H]2C(=O)N1Cc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.73
TSHR P16473 3/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
KMT2A Q03164 3/20 0.63
MEN1 O00255 2/20 0.63
F2 P00734 1/20 0.57
PLG P00747 1/20 0.57
ELANE P08246 1/20 0.57
CTSG P08311 1/20 0.57
CMA1 P23946 1/20 0.57
CTRC Q99895 1/20 0.57
GSK3A P49840 1/20 0.53
GSK3B P49841 1/20 0.53
MGLL Q99685 1/20 0.53
EP300 Q09472 1/20 0.53
MAPK1 P28482 3/20 0.53
ACHE P22303 1/20 0.52
MT-CO2 P00403 2/20 0.51
ALOX5 P09917 2/20 0.51
CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13783795 1.00 ALDH1A1 (0.73) ALDH1A1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL1023519 1.00 ALDH1A1 (0.73) ALDH1A1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL13291895 0.89 ALDH1A1 (0.65) ALDH1A1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL3716740 0.85 ALDH1A1 (0.93) ALDH1A1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL7829113 0.85 ALDH1A1 (0.93) ALDH1A1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL6747735 0.85 ALDH1A1 (1.00) ALDH1A1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL6747736 0.85 ALDH1A1 (1.00) ALDH1A1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL5770320 0.85 ALDH1A1 (0.69) ALDH1A1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL8383162 0.85 ALDH1A1 (1.00) ALDH1A1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL3236740 0.85 ALDH1A1 (0.69) ALDH1A1TSHRSMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008298-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-08-30 US disclosed
US-8008298-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-08-30 US disclosed
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2010-10-21 US disclosed
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2010-10-21 US disclosed
WO-2009106441-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors SYK, ZAP70, TYK2 ALDH1A1 4082/4885TSHR 1966/4885SMN1; SMN2 4777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.